How Will Aducanumab Approval Change Clinical Practice?
The U.S. Food and Drug Administrations green light for aducanumab (Aduhelm) is poised to upend research and clinical practice. In research settings, many scientists wonder if this decision will set a precedent for future approvals without proof of efficacy, and whether it will help or hamper research into additional drugs (see Part 1 and Part 2 of this series). In treatment settings, Alzheimers physicians are facing a deluge of calls. They are also facing a sea of unknowns, ranging from which patients qualify for aducanumab treatment to what its contraindications may be and how long patients should stay on it (see Part 4 of this series).